| Literature DB >> 34335034 |
Yisiak Oumer1, Belayneh Regasa Dadi1, Mohamed Seid1, Gelila Biresaw2, Aseer Manilal1.
Abstract
INTRODUCTION: Catheter-associated urinary tract infections (CAUTIs) are the most common nosocomial infection and a leading cause of morbidity. The aim of this study was to determine the prevalence, associated factors and antibiogram of the bacterial isolates among CAUTIs patients.Entities:
Keywords: antimicrobial susceptibility; catheter-associated urinary tract infections; risk factors; uropathogens
Year: 2021 PMID: 34335034 PMCID: PMC8318706 DOI: 10.2147/IDR.S311229
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Socio-demographic, Clinical Characteristics and Associated Factors Among Patients with Symptomatic CAUTIs
| Variable and Category | Total Tested | Number and % of Bacterial CAUTIs | COR [95% CI] | P-value | AOR [95% CI] | P-value |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male | 156 (67.5) | 30 (76.9) | 1 | 1 | 1 | 1 |
| Female | 75 (32.5) | 9 (23.1) | 0.5[0.2–1.2] | 0.17 | 1.1[0.1–7.7] | 0.91 |
| Age groups in years | ||||||
| 18–29 | 27 (11.7) | 1 (2.6) | 1 | 1 | 1 | 1 |
| 30–39 | 40 (17.3) | 7 (17.9) | 5.5[0.6–47.6] | 0.121 | 8.6[0.8–84.8] | 0.06 |
| 40–49 | 44 (19.0) | 3 (7.7) | 1.9[0.1–19.2] | 0.582 | 4.2[0.2–27.9] | 0.31 |
| 50–59 | 48 (20.8) | 3 (7.7) | 1.7[0.1–17.5] | 0.641 | 1.7[0.0–38.5] | 0.71 |
| 60–69 | 44 (19.0) | 25 (66.6) | 13.8[1.7–108] | 0.012 | 7.3[0.2–212.0] | 0.24 |
| ≥70 | 28 (12.1) | - | - | - | ||
| Admission ward | ||||||
| Medical | 38 (16.5) | 4 (10.3) | 1 | 1 | 1 | 1 |
| Surgical | 143 (61.9) | 28 (71.8) | 2.0[0.6–6.3] | 0.20 | 2.8[0.1–80.8] | 0.53 |
| Obs/Gyn | 47 (20.3) | 6 (15.4) | 1.2[0.3–4.7] | 0.75 | 40.78[0.3–4.8] | 0.11 |
| ICU | 3 (1.3) | 1 (2.6) | 4.2[0.3–58.0] | 0.27 | 18.1[0.49–78] | 0.13 |
| Reason for admission | ||||||
| Benign prostatic hyperplasia | 81 (35.1) | 25 (64.1) | 5.8[0.7–46.8] | 0.09 | 9.1[0.2–2] | 0.21 |
| Others | 150(65.2) | 14 (35.9) | 1 | |||
| Reason for catheterization | ||||||
| Urine incontinence | 9 (3.9) | 1 (2.6) | 1 | 1 | 1 | 1 |
| Pre/post-operative drainage | 111 (48.1) | 9 (23.1) | 0.8[0.09–7.5] | 0.8 | 1.3[0.3–5.92] | 0.6 |
| Urine output measurement | 16 (6.9) | 1 (2.6) | 0.5[0.02–9.7] | 0.67 | 3.8[1.1–13.61] | 0.03 |
| Urine retention | 82 (35.5) | 26 (66.7) | 3.4[0.4–28.7] | 0.25 | 1.[0.2–11.07] | 0.60 |
| Keeping patient dry | 13 (5.6) | 2 (5.1) | 1.4[0.1–18.] | 0.77 | 3.3[0.12–89.7] | 0.47 |
| Place of catheter insertion | ||||||
| Operation room | 76 (32.9) | 8 (20.5) | 1 | 1 | 1 | |
| Emergency ward | 49 (21.2) | 7 (17.9) | 1.4[0.4–4.1] | 0.52 | 1.3[0.3–5.9] | 0.65 |
| Surgical ward | 60 (26.0) | 18 (46.2) | 3.6[1.4–9.1] | 0.00 | 3.8[1.1–13.6] | 0.03 |
| Obs and Gyn ward | 19 (8.2) | 3 (7.7) | 1.5[0.3–6] | 0.52 | 1.66[0.2–11.0] | 0.60 |
| Medical ward | 27 (11.7) | 3 (7.7) | 1.0[0.2–4.3] | 0.93 | 3.314[0.1–89] | 0.47 |
| Duration of Catheterization | ||||||
| Short duration (<7 days) | 140 (60.6) | 15 (38.5) | 1 | 1 | 1 | 1 |
| Long duration (<7 days) | 91 (39.4) | 24 (61.5) | 3.0[1.5–6.2] | 0.00 | 3.08[1.2–7.4] | 0.01 |
| Comorbidity | ||||||
| Chronic heart disease | 12 (5.2) | 2 (5.1) | 0.9[0.2–4.6] | 0.98 | - | - |
| Chronic kidney disease | 5 (2.2) | 1 (2.6) | 1.2[0.1–1.3] | 0.85 | - | - |
| Diabetes mellitus | 8 (20.5) | 3.0[1.9–7.7] | 0.02 | 5.1[1.4–19] | 0.013 | |
| Hypertension | 34 (17.7) | 5 (2.2) | 2.2[0.7–6.6] | 0.16 | 1.6[0.0.3–7.1] | 0.5 |
| Hospitalization | ||||||
| <10 days | 134 (58.0) | 13 (33.3) | 1 | |||
| ≥10 days | 97 (42.0) | 26 (66.7) | 3.4[1.6–7.0] | 0.00 | 2.4[0.9–6.03] | 0.05 |
| History of catheterization | 50 (21.6) | 8 (20.5) | 3.0[1.1–7.7] | 0.02 | 1.12[0.4–3.40] | 0.74 |
| Taking antimicrobial prophylaxis | 158 (68.4) | 31 (79.5) | 1.9[0.8–4.5] | 0.10 | 0.1[0.01–2.76] | 0.20 |
Abbreviations: CAUTIs, catheter-associated urinary tract infections; COR, crude odds ratio; AOR, adjusted odds ratio; CI, confidence interval; Obs/Gyn, obstetrics and gynecology; ICU, intensive care unit.
Figure 1Bacterial profiles among CAUTI patients at Arba-Minch General Hospital, South Ethiopia (proportion of bacterial isolates).
Antimicrobial Susceptibility Pattern of Gram-Negative Bacteria Isolated from Urine Culture of Symptomatic CAUTIs Patients
| Antimicrobial Agents Tested | DSP | Total N = 30 | |||||
|---|---|---|---|---|---|---|---|
| No.(%) | No.(%) | No. (%) | No. (%) | No. (%) | No. (%) | ||
| Ampicillin | S | 0 | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
| R | 30(100) | 17(100) | 9(100) | 1(100) | 2(100) | 1(100) | |
| Gentamicin | S | 9(30) | 4(23.5) | 4(44.5) | 0(0) | 1(50) | 0(0) |
| R | 21(70) | 13(64.7) | 5(55.5) | 1(100) | 1(50) | 1(100) | |
| Amikacin | S | 26(86.6) | 15(88.2) | 7(77.8) | 1(100) | 2(100) | 1(100) |
| R | 4(13.3) | 2(11.8) | 2(22.2) | 0(0) | 0(0) | 0 | |
| Tetracycline | S | 4(13.3) | 2(11.3) | 1(11) | 0(0) | 1(50) | 0(0) |
| R | 26(86.6) | 15(88.2) | 8(89) | 1(100) | 1(50) | 1(100) | |
| Ciprofloxacin | S | 8(26.6) | 3(17.6) | 3(33.3) | 0(0) | 2(100) | 0(0) |
| R | 22(73.3) | 14(82.4) | 6(66.7) | 1(100) | 0 | 1(100) | |
| Norfloxacin | S | 8(26.6) | 3(17.7) | 4(44.4) | 0(0) | 2(100) | 0(0) |
| R | 22(73.3) | 14(82.3) | 5(55.6) | 1(100) | 0 | 1(100) | |
| Nalidixic-acid | S | 7(23.3) | 2(11.3) | 4(44.4) | 0(0) | 1(50) | 0(0) |
| R | 23(76.6) | 15(88.2) | 5(55.6) | 1(100) | 1(50) | 1(100) | |
| Nitrofurantoin | S | 29(99.6) | 17(100) | 9(100) | 1(100) | 2(100) | 0(0) |
| R | 1(0.5) | 0(0) | 0(0) | 0(0) | 0(0) | 1(0) | |
| Cotrimoxazole | S | 3(10) | 2(11.8) | 1(11.1) | 0(0) | 0(0) | 0(0) |
| R | 27(90) | 15 | 8(88.9) | 1(100) | 2(100) | 1(100) | |
| Cefepime | S | 9(30) | 5(29.4) | 3(33.3) | 0(0) | 1(50) | 0(0) |
| R | 21(70) | 12(70.6) | 6(66.7) | 1(100) | 1(50) | 1(100) | |
| Ceftriaxone | S | 9(30) | 5(29.44) | 3(33.3) | 0(0) | 1(50) | 0(0) |
| R | 21(70) | 12(70.6) | 6(66.7) | 1(100) | 1(50) | 1(100) | |
| Cefoxitin | S | 6(33.3) | 5(29.4) | 4(44.4) | 0(0) | 1(50) | 0 |
| R | 24(86.7) | 12(70.6) | 5(55.6) | 1(100) | 1(50) | 1(100) | |
| Meropenem | S | 26(86.7) | 15(88.2) | 7(77.8) | 1(100) | 2(100) | 1(100) |
| R | 4(13.3) | 2(11.3) | 2(22.2) | 0 | 0 | 0(0) | |
| MDR | Yes | 29(96.6) | 16(94.1) | 9(100) | 1(100) | 1(100) | 1(100) |
| No | 1(0.4%) | 1 | 0 | 0 | 0 | 0 |
Abbreviations: DSP, drug susceptibility pattern; MDR, multidrug resistant; spp, species; S, sensitive; I, intermediate; R, resistance.
Antimicrobial Susceptibility Pattern of Gram-Positive Bacterial Isolates from Urine Culture of Symptomatic CAUTIs Patients
| Drugs | Bacterial Isolates | ||||
|---|---|---|---|---|---|
| DSP | CoNS (n = 1) | Total (n = 9) | |||
| PEN | S | 1(33.3) | 0(0) | 1(20%) | 2(22.2%) |
| I | 0(0) | 0(0) | 0(0) | 0(0) | |
| R | 2(66.7%) | 1(100%) | 4(80%) | 7(77.8%) | |
| AMP | S | NA | NA | 3(60%) | 3(60%) |
| I | NA | NA | 0(0) | 0(0) | |
| R | NA | NA | 2(40%) | 2(40%) | |
| GEN | S | 1(33.3%) | 0(0) | NA | 1(25%) |
| I | 1(33.3%) | 0(0) | NA | 1(25%) | |
| R | 1(33.3%) | 1(100%) | NA | 2(50%) | |
| ERY | S | 1(33.3%) | 0(0) | 1(20%) | 2(22.2%) |
| I | 0(0) | 0(0) | 0(0) | 0(0) | |
| R | 2(66.7%) | 1(100%) | 4(80%) | 7(77.8%) | |
| TET | S | 2(66.7%) | 0(0) | 1(20%) | 3(33.3%) |
| I | 0(0) | 0(0) | 0(0) | 0(0) | |
| R | 1(33.3%) | 1(100%) | 4(80%) | 6(66.7%) | |
| CPR | S | 2(66.7%) | 1(100%) | 2(40%) | 5(55.6%) |
| I | (0) | 0(0) | 0(0) | 0(0) | |
| R | 1(33.3%) | 0(0) | 3(60%) | 4(44.4%) | |
| NOR | S | 2(66.7%) | 1(100%) | 1(20%) | 3(33.3%) |
| I | 0(0) | 0(0) | 0(0) | 1(11.1%) | |
| R | 1(33.3%) | 0(0) | 4(80%) | 5(55.6%) | |
| NIT | S | 3(100%) | 1(100%) | 4(80%) | 8(89.9%) |
| I | 0(0) | 0(0) | 1(20%) | 1(11.1%) | |
| R | 0(0) | 0(0) | 0(0) | 0(0) | |
| COT | S | 1(33.3%) | 0(0) | NA | 1(25%) |
| I | 0(0) | 0(0) | NA | 0(0) | |
| R | 2(66.7%) | 1(100%) | NA | 3(75%) | |
| CHL | S | 2(66.7%) | 1(100%) | 1(20%) | 4(44.4%) |
| I | 0(0) | 0(0) | 0(0) | ||
| R | 1(33.3%) | 0(0) | 4(80%) | 5(55.6%) | |
| VAN | S | NA | NA | 4(80%) | 4(80%) |
| I | NA | NA | 0(0) | 0(0) | |
| R | NA | NA | 1(20%) | 1(20%) | |
| CXT | S | 2(66.7%) | 0(0) | NA | 2(50%) |
| I | 0(0) | 0(0) | NA | 0(0) | |
| R | 1(33.3%) | 1(100%) | NA | 2(50%) | |
Abbreviations: NA, not applicable; DSP, drug susceptibility pattern; PEN, penicillin; AMP, ampicillin; GEN, gentamicin; ERY, erythromycin; TET, tetracycline; CPR, ciprofloxacin; NOR, norfloxacin; NIT, nitrofurantoin; CHL, chloramphenicol; VAN, vancomycin; CTR, ceftriaxone; CXT, cefoxitin; S, sensitive; I, intermediate; R, resistance; spp, species.
Percentage of the Most Common MDR Profiles Among Patients with Symptomatic CAUTIs
| Antimicrobials Combination | Total (n = 30) | Klebsiella | |||||
|---|---|---|---|---|---|---|---|
| Antimicrobial Class | Profile of MDR | ||||||
| N0. % | N0. % | N0. % | N0. % | N0. % | N0. % | ||
| Penicillins, quinolones, and sulfonamides | AMP, COT, CPR | 2(6.6) | 1(5.8) | 1(11.1) | – | – | – |
| Penicillins, quinolones, cephalosporins | AMP, CPR, TET | 2(6.6) | 1(5.8) | 1(11.1) | – | – | – |
| Penicillins, quinolones, cephalosporins, sulfonamides | AMP, TET, (CFP, CTR), CPR, COT | 2(6.6) | 1(5.8) | 1(11.1) | – | – | – |
| Penicillins, sulfonamides, fluoroquinolones, cephalosporins, aminoglycoside | AMP, TET, (CFP, CTR, CXT), CPR, COT, GEN | 4(13.3) | 2(11.7) | 2(22.2) | – | – | – |
| Penicillins, quinolones, cephalosporins, aminoglycoside, cephamycins | AMP,(CFP, CTR, CXT), CPR, COT, GEN, CTX | 9(30) | 3(17.6) | 4(44.4) | – | 1(100) | 1(100%) |
| Penicillins, sulfonamides, quinolones, cephalosporins, aminoglycoside, carbapenems | AMP, (CFP, CTR, CXT), CPR, COT, GEN, CTX, MER | 10(33.3) | 8(47) | 1(11.1) | 1(50) | – | – |
| Total | 29(96.6) | 16(94.1) | 9(100) | 1 | 1 | 1 | |
Abbreviations: AMP, ampicillin; GEN, gentamicin; TET, tetracycline; CPR, ciprofloxacin; CTR, ceftriaxone; CXT, cefoxitin; COT, cotrimoxazole; CFP, cefepime; MER, meropenem; spp, species.
Biofilm Formation of Bacterial Isolates from CAUTIs Patients of Arba-Minch General Hospital, 2019
| Biofilm Formation | |||||
|---|---|---|---|---|---|
| Bacterial Isolates | Biofilm Forming | ||||
| No. (%) | SBF (%) | MBF (%) | WBF (%) | NBF (%) | |
| 17(40.5) | 5(29.4%) | 4(23.5%) | 2(11.8%) | 6(35.3%) | |
| 9(21.4) | 2(22.2%) | 2(22.2%) | 2(22.2%) | 3(33.3%) | |
| 1(2.4) | _ | 1(100%) | _ | _ | |
| 2(4.8) | 1(50%) | _ | _ | 1(50%) | |
| 1(2.4) | 1(100%) | _ | _ | _ | |
| 3(7.1) | 2(66.7%) | 1(33.3%) | |||
| 3(7.1) | 1(33.3%) | 1(33.3%) | _ | 1(33.3%) | |
| CoNS | 1(2.4) | 1(100%) | _ | _ | _ |
| 5(11.9) | 3(60%) | 1(20%) | _ | 1(20%) | |
| Total | 42(100) | 16(53.3%) | 10(33.3%) | 4(13.3%) | 12(28.6%) |
Abbreviations: BF, biofilm formers; NBF, non-biofilm formers; SBF, strong biofilm formers; MBF, moderate biofilm formers; WBF, weak biofilm formers; CONS, coagulase-negative staphylococci; spp., species.